Indonesia Lags Behind in Blood Cancer Transplantation, Challenges Remain
Bone marrow transplantation services in Indonesia continue to face significant hurdles. In addition to limitations in human resources and the number of transplantation centres, the volume of procedures performed domestically remains far below that of several Southeast Asian neighbours.
Data shows that in 2023, the number of bone marrow transplantations in Indonesia was recorded at 19 patients. This figure is much lower than Malaysia, which reached 409 patients, Singapore with 277, Vietnam with 149, and the Philippines with 80.
Bone marrow transplantation can serve as a definitive therapy for patients with certain types of blood cancer. The procedure involves replacing problematic blood-forming cells with new, healthy cells.
Deputy Minister of Health Dante Saksono Harbuwono stated that bone marrow is the production site for blood cells, making the replacement of faulty cells with healthy ones a vital component of blood cancer therapy. “The source of blood cancer is the factory. Where is the factory? In the bone marrow,” Dante said during the ‘A Decade of Hope’ event at Dharmais Cancer Hospital, Jakarta.
One hospital developing these services is Dharmais Cancer Hospital. Over the last decade, the hospital has performed transplantations on 16 patients. In 2011, the Dharmais team was sent to Singapore General Hospital to strengthen their autologous transplantation capabilities. Five years later, the service began to materialise at Dharmais. The team later deepened their expertise in allogeneic transplantation techniques at the National Cancer Center (NCC) in Korea in 2019.
While the development of these services was temporarily halted by the Covid-19 pandemic, competency improvements have continued until services resumed. Of the 16 patients who have undergone transplantation, two died due to complications, and one died approximately eight months after the procedure due to a new infection, while the others remain stable.
The low number of transplantations in Indonesia indicates that the development of medical technology is not the only challenge. The availability of medical personnel with specialised competencies and the number of active transplantation centres are also critical factors in increasing patient access to such therapy. Furthermore, cost remains a significant consideration in the development of transplantation services in Indonesia.
This situation leads many patients to consider treatment abroad. The government hopes that the growing capability of domestic hospitals will reduce this necessity. Dante stated that the ability to perform transplantations in Indonesia is expected to provide access to definitive therapy for blood cancer patients without the need to travel overseas.
In addition to strengthening service capacity, Dharmais is also preparing to develop haploidentical transplantation. This technique allows a donor with approximately 50% compatibility to serve as a donor, meaning family members such as parents or children can act as alternatives when a fully matched donor is unavailable.
Source: jawawa.id (https://jawawa.id/newsitem/indonesia-lags-behind-in-blood-cancer-transplantation-challenges-remain-1790754818)
Originally published by CNBC Indonesia (https://www.cnbcindonesia.com/lifestyle/20260930125822-33-772119/transplantasi-kanker-darah-ri-masih-tertinggal-ini-tantangannya), translated from Indonesian